We are live on
!
Find out more
BCM
Boone Capital Management Portfolio holdings
AUM
$326M
1-Year Est. Return
86.31%
This Fund
S&P 500
This Quarter
Est. Return
+3.42%
1 Year Est. Return
+86.31%
3 Year Est. Return
+255.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$317M
AUM Growth
+$38.4M
(+14%)
Cap. Flow
+$37.6M
Cap. Flow
% of AUM
11.87%
Top 10 Holdings %
Top 10 Hldgs %
88.65%
Holding
16
New
3
Increased
9
Reduced
1
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Globus Medical
GMED
|
+$24M |
| 2 |
Mirum Pharmaceuticals
MIRM
|
+$10.7M |
| 3 |
BridgeBio Pharma
BBIO
|
+$8.89M |
| 4 |
Biogen
BIIB
|
+$8.89M |
| 5 |
Cigna
CI
|
+$5.52M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$11.9M |
| 2 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$9.54M |
| 3 |
Baxter International
BAX
|
+$9.3M |
| 4 |
TBRG
TruBridge
TBRG
|
+$8.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.54% |
| 2 | Financials | 13.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Unum
UNM
$13.7B
| $42.7M | 13.46% |
867,565
+10,000
| +1% | +$489K |
|
|
2
Cigna
CI
$75.2B
| $37.2M | 11.73% |
129,917
+19,366
| +18% | +$5.52M |
|
3
Molina Healthcare
MOH
$10.1B
| $37.1M | 11.71% |
113,178
+6,659
| +6% | +$2.1M |
|
4
Danaher
DHR
$137B
| $32M | 10.11% |
145,696
+21,718
| +18% | +$4.84M |
|
5
Enovis
ENOV
$1.65B
| $26.5M | 8.36% |
502,731
+74,938
| +18% | +$4.37M |
|
6
Amgen
AMGN
$207B
| $26.4M | 8.32% |
98,126
+14,627
| +18% | +$3.65M |
|
|
7
Biogen
BIIB
$30.5B
| $24.7M | 7.79% |
96,115
+33,238
| +53% | +$8.89M |
|
|
8
Globus Medical
GMED
$10.7B
| $21.3M | 6.71% |
+428,452
| New | +$24M |
|
|
9
Baxter International
BAX
$13.7B
| $17.7M | 5.59% |
469,405
-218,296
| -32% | -$9.3M |
|
10
Quanterix
QTRX
$164M
| $15.4M | 4.87% |
568,544
+67,400
| +13% | +$1.67M |
|
11
IDEAYA Biosciences
IDYA
$3.46B
| $15.4M | 4.86% |
570,682
+74,249
| +15% | +$1.88M |
|
|
12
Mirum Pharmaceuticals
MIRM
$6.74B
| $12.3M | 3.89% |
+389,791
| New | +$10.7M |
|
|
13
BridgeBio Pharma
BBIO
$15.8B
| $8.26M | 2.61% |
+313,381
| New | +$8.89M |
|
|
14
AbbVie
ABBV
$449B
| – | – |
-88,026
| Closed | -$11.9M |
|
|
TBRG
15
DELISTED
TruBridge
TBRG
| – | – |
-349,245
| Closed | -$8.62M |
|
|
CERE
16
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| – | – |
-300,000
| Closed | -$9.54M |
|
Similar funds
ISFAN
JHWEPV
AFA
ECH
DCM
MVM
CCG
TC
Boone Capital Management's Q3 2023 Portfolio in Review
As of Q3 2023, Boone Capital Management held 16 positions worth $317M, up 14% from $279M the previous quarter. Its ten largest holdings account for 89% of the portfolio.
Boone Capital Management deployed $37.6M of net new capital in Q3 2023, opening 3 new positions and adding to 9 existing holdings. Its largest new stake was Globus Medical: 428,452 shares worth $21.3M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 85% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Baxter International, an estimated $9.3M trimmed.
- Boone Capital Management's largest Q3 2023 buy was Globus Medical: 428,452 shares worth $21.3M.
- Boone Capital Management added most to Biogen in Q3 2023, an estimated $8.89M increase.
- Boone Capital Management's biggest Q3 2023 reduction was Baxter International, cutting an estimated $9.3M.
- Boone Capital Management fully exited AbbVie in Q3 2023, selling an estimated $11.9M.
- Boone Capital Management's ten largest holdings make up 89% of its $317M portfolio in Q3 2023.
- Boone Capital Management opened 3 new positions and closed 3 in Q3 2023.
- Boone Capital Management's portfolio value rose 14% quarter-over-quarter to $317M.
Based on Boone Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.